Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Capecitabine × 1 year × Clear all

Status

Recruiting 131 Active not recruiting 87 Not yet recruiting 47 Completed 35 Terminated 12 Withdrawn 3 Suspended 2 Enrolling by invitation 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

zenocutuzumab 1 tucatinib 1 talquetamab 1 niraparib 1 futibatinib 1 erdafitinib 1 cemiplimab 1 adagrasib 1 Trastuzumab 1 TIC10 compound 1 Prednisone 1 Prednisolone 1 Capecitabine 1 Amifampridine 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Seagen Inc.

Approved for marketing

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡